| Sep-10-19 11:33AM | FDA: No Adcom Meeting For Intra-Cellular's Schizophrenia Drug Benzinga |
| 07:30AM | Intra-Cellular Therapies Provides Lumateperone Regulatory Update GlobeNewswire |
| Aug-28-19 08:48AM | How Should Investors React To Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) CEO Pay? Simply Wall St. |
| Aug-19-19 06:00AM | 5 Biggest New Drug Approvals Potentially on the Way in 2019 Motley Fool |
| Aug-07-19 08:00AM | Intra-Cellular Therapies Provides Corporate Update and Reports Second Quarter 2019 Financial Results GlobeNewswire |
| Aug-06-19 08:00AM | Intra-Cellular Therapies to Present at the Canaccord Genuity 39th Annual Growth Conference GlobeNewswire |
| Aug-05-19 07:30AM | Intra-Cellular Therapies to Host Conference Call to Provide Regulatory Update Following Recent Meeting with FDA GlobeNewswire +8.46% |
| Jul-24-19 10:58AM | Biotech Stock Roundup: BIIB Q2 Earnings Top & CELG's Otezla Label Expanded Zacks |
| Jul-23-19 07:30PM | Intra-Cellular Therapies Provides Update on FDA Advisory Committee Meeting for Lumateperone for the Treatment of Schizophrenia GlobeNewswire -31.64% |
| 04:30PM | Why PulteGroup, Intra-Cellular Therapies, and Clear Channel Outdoor Slumped Today Motley Fool |
| 07:11AM | Is Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Potentially Underrated? Simply Wall St. |
| Jul-09-19 11:10AM | A Look At Benzinga Pro's Most-Searched Tickers For July 9, 2019 Benzinga |
| 09:49AM | Company News For Jul 9, 2019 Zacks |
| 09:45AM | Intra-Cellular Therapies' Candidate Fails in Phase III Study Zacks |
| Jul-08-19 04:51PM | Why Deutsche Bank, Intra-Cellular Therapies, and Coherus BioSciences Slumped Today Motley Fool -13.08% |
| 01:50PM | A Look At Benzinga Pro's Most-Searched Tickers For July 8, 2019 Benzinga |
| 11:34AM | Why Intra-Cellular Therapies Is Tanking Today Motley Fool |
| 08:58AM | Intra-Cellular Therapies stock down 15% after disappointing Phase 3 trial results MarketWatch |
| 08:52AM | Intra-Celluar Therapies Falls Following Results For Treatment Of Bipolar Depression Benzinga |
| 07:54AM | UPDATE 1-Intra-Cellular drug fails one of two bipolar depression studies; shares fall Reuters |
| 07:18AM | Intra-Cellular drug fails one of two bipolar depression studies Reuters |
| 07:14AM | Intra-Cellular announces positive results in late-stage trials of treatment for bipolar depression MarketWatch |
| 07:00AM | Intra-Cellular Therapies Announces Positive Top-line Results from a Phase 3 Trial of Lumateperone in Patients with Bipolar Depression GlobeNewswire |
| Jul-06-19 02:45PM | The Week Ahead In Biotech: Conferences, Clinical Trial Readouts And Earnings Benzinga |
| Jul-05-19 02:49PM | Intra-Cellular Shares May Double on Bipolar Depression Data Bloomberg |
| 08:43AM | Are Options Traders Betting on a Big Move in Intra-Cellular Therapies (ITCI) Stock? Zacks |
| Jul-02-19 08:00AM | Intra-Cellular Therapies Appoints Karen Patruno Sheehy, Esq. as Senior Vice President, Chief Compliance Officer GlobeNewswire |
| Jul-01-19 12:55PM | 7 Stocks on Sale the Insiders Are Buying InvestorPlace +8.09% |
| Jun-26-19 02:06PM | Here is What Hedge Funds Think About Intra-Cellular Therapies Inc (ITCI) Insider Monkey |
| Jun-19-19 08:00AM | Intra-Cellular Therapies to Present at JMP Securities Life Sciences Conference GlobeNewswire |
| Jun-17-19 10:11AM | Before You Buy Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), Consider Its Volatility Simply Wall St. +13.11% |
| 08:39AM | Implied Volatility Surging for Intra-Cellular (ITCI) Stock Options Zacks |
| Jun-13-19 08:55AM | Intra-Cellular Therapies Announces FDA Advisory Committee Meeting to Review the NDA for Lumateperone for the Treatment of Schizophrenia in Adults GlobeNewswire +8.63% |
| May-30-19 08:00AM | Intra-Cellular Therapies to Present at Jefferies 2019 Global Healthcare Conference GlobeNewswire |
| May-20-19 08:41AM | 2 Biotech Names See Directors Direct Cash to Their Shares TheStreet.com |
| May-17-19 03:14AM | Edited Transcript of ITCI earnings conference call or presentation 8-May-19 12:30pm GMT Thomson Reuters StreetEvents |
| May-16-19 08:00AM | Intra-Cellular Therapies to Present at 2019 RBC Capital Markets Global Healthcare Conference GlobeNewswire |
| May-15-19 08:00AM | Intra-Cellular Therapies Announces Presentations on Lumateperone Schizophrenia Program at the American Psychiatric Association (APA) Annual Meeting GlobeNewswire |
| May-10-19 01:15PM | Such Is Life: How Intra-Cellular Therapies (NASDAQ:ITCI) Shareholders Saw Their Shares Drop 57% Simply Wall St. |
| May-08-19 04:06PM | Heres What Hedge Funds Think About Intra-Cellular Therapies Inc (ITCI) Insider Monkey |
| 01:26PM | Intra-Cellular Therapies, Inc. (ITCI) Q1 2019 Earnings Call Transcript Motley Fool |
| 07:42AM | Intra-Cellular: 1Q Earnings Snapshot Associated Press |
| 07:30AM | Intra-Cellular Therapies Reports First Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire |
| May-02-19 08:00AM | Intra-Cellular Therapies to Host First Quarter 2019 Financial Results Conference Call and Webcast GlobeNewswire |
| Apr-29-19 08:56AM | Are Options Traders Betting on a Big Move in Intra-Cellular Therapies (ITCI) Stock? Zacks |
| Apr-16-19 08:00AM | Intra-Cellular Therapies Mourns the Passing of Co-Founder and Nobel Laureate, Dr. Paul Greengard GlobeNewswire |
| Apr-15-19 07:00AM | Intra-Cellular Therapies Presents Additional Results From Long-term Open Label Safety Study of Lumateperone at the 2019 Congress of the Schizophrenia International Research Society GlobeNewswire |
| Apr-02-19 11:40AM | Investors Who Bought Intra-Cellular Therapies (NASDAQ:ITCI) Shares Three Years Ago Are Now Down 61% Simply Wall St. +7.91% |
| Mar-26-19 07:00AM | Intra-Cellular Therapies Continues to Strengthen Its Commercial Leadership Team; John A. Bardi Appointed as Senior Vice President, Market Access, Policy and Government Affairs GlobeNewswire |
| Mar-05-19 08:00AM | Intra-Cellular Therapies to Present at The Cowen and Company 39th Annual Health Care Conference GlobeNewswire |
| Mar-04-19 06:01PM | Edited Transcript of ITCI earnings conference call or presentation 27-Feb-19 1:30pm GMT Thomson Reuters StreetEvents |
| Feb-27-19 11:30AM | Intra-Cellular Therapies Inc (ITCI) Q4 2018 Earnings Conference Call Transcript Motley Fool +6.66% |
| 07:30AM | Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Corporate Update GlobeNewswire |
| Feb-21-19 08:00AM | Intra-Cellular Therapies to Present at the 8th Annual SVB Leerink Global Healthcare Conference GlobeNewswire |
| Feb-20-19 08:00AM | Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2018 Financial Results Conference Call and Webcast GlobeNewswire |
| Feb-19-19 07:40AM | Detailed Research: Economic Perspectives on Tesla, Kura Oncology, ASML Holding N.V, Applied Industrial Technologies, Raven Industries, and Intra-Cellular Therapies What Drives Growth in Today's Competitive Landscape GlobeNewswire |
| Feb-14-19 03:30PM | Here Are 5 Biotech Stocks To Love This Valentine's Day: Analyst Investor's Business Daily |
| Jan-23-19 12:09PM | Read This Before Buying Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Simply Wall St. |
| Jan-03-19 11:20AM | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intra-Cellular Therapies, Inc. - ITCI ACCESSWIRE |
| 08:00AM | Intra-Cellular Therapies to Present at the 37th Annual J.P. Morgan Healthcare Conference GlobeNewswire |
| Dec-30-18 02:26PM | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intra-Cellular Therapies, Inc. - ITCI GlobeNewswire |
| Dec-28-18 12:10AM | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intra-Cellular Therapies, Inc. - ITCI ACCESSWIRE |
| Dec-19-18 06:21AM | Is Intra-Cellular Therapies Inc (ITCI) A Good Stock To Buy? Insider Monkey -5.65% |
| Dec-18-18 02:01PM | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intra-Cellular Therapies, Inc. - ITCI PR Newswire |
| 01:00PM | SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Intra-Cellular Therapies, Inc. (ITCI) GlobeNewswire |
| 08:52AM | Intra-Cellular Therapies stock down 22% after discontinuation of Phase 3 trial MarketWatch |
| 08:30AM | Intra-Cellular Therapies Announces Update on ITI-007-201 Clinical Trial for Treatment of Agitation in Patients with Probable Alzheimer's Disease GlobeNewswire |
| Dec-17-18 01:13PM | How Should Investors React To Intra-Cellular Therapies, Inc.s (NASDAQ:ITCI) CEO Pay? Simply Wall St. -5.02% |
| Dec-11-18 05:30PM | Intra-Cellular Therapies Announces Favorable Results From Long-Term Open-Label Safety Switching Study With Lumateperone in Patients with Schizophrenia at the 57th Annual Meeting of the American College of Neuropsychopharmacology GlobeNewswire |
| 07:00AM | Intra-Cellular Therapies Announces FDA Acceptance of New Drug Application for Lumateperone for the Treatment of Schizophrenia GlobeNewswire |
| Nov-20-18 07:32AM | Edited Transcript of ITCI earnings conference call or presentation 7-Nov-18 1:30pm GMT Thomson Reuters StreetEvents |
| Nov-07-18 02:53PM | Does Intra-Cellular Therapies Inc (NASDAQ:ITCI) Have A High Beta? Simply Wall St. |
| 10:37AM | Intra-Cellular: 3Q Earnings Snapshot Associated Press |
| 07:00AM | Intra-Cellular Therapies Provides Corporate Update and Reports Third Quarter 2018 Financial Results GlobeNewswire |
| Nov-01-18 08:00AM | Intra-Cellular Therapies to Host Third Quarter 2018 Financial Results Conference Call and Webcast GlobeNewswire +9.66% |
| Oct-25-18 07:20AM | Investor Expectations to Drive Momentum within Tribune Media, Intra-Cellular Therapies, Icahn Enterprises, NVE, PetMed Express, and United Fire Group Discovering Underlying Factors of Influence GlobeNewswire +6.96% |
| Oct-23-18 07:00AM | Intra-Cellular Therapies Announces Favorable Safety Profile for ITI-214 in a Phase 1/2 Clinical Trial in Patients with Parkinsons Disease GlobeNewswire |
| Oct-17-18 08:00AM | Intra-Cellular Therapies Presents Results from ITI-214 Phase 1/2 Clinical Trial in Patients with Parkinsons Disease at 2018 American Neurological Association Annual Meeting GlobeNewswire |
| Oct-16-18 08:00AM | Intra-Cellular Therapies Appoints Mark Neumann as Executive Vice President, Chief Commercial Officer GlobeNewswire +5.49% |
| Oct-15-18 08:35AM | Intra-Cellular Therapies Sees Hammer Chart Pattern: Time to Buy? Zacks |
| Oct-08-18 09:00AM | Options Traders Expect Huge Moves in Intra-Cellular (ITCI) Stock Zacks -5.10% |
| Sep-28-18 07:00AM | Intra-Cellular Therapies Completes Submission of New Drug Application for Lumateperone for Treatment of Schizophrenia GlobeNewswire |
| Sep-26-18 08:00AM | Intra-Cellular Therapies to Present at the Cantor Fitzgerald Global Healthcare Conference GlobeNewswire |
| Sep-25-18 07:00AM | Intra-Cellular Therapies Appoints Michael Olchaskey as Senior Vice President, Head of Regulatory Affairs GlobeNewswire +6.31% |
| Sep-18-18 08:54AM | Is Intra-Cellular Therapies Inc (NASDAQ:ITCI) A Financially Sound Company? Simply Wall St. |
| Sep-05-18 07:55AM | New Research: Key Drivers of Growth for Intra-Cellular Therapies, The, Bassett Furniture Industries, NVE, Equity Bancshares, and Cable One Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire |
| Aug-20-18 08:00AM | Intra-Cellular Therapies Appoints Dr. Suresh Durgam as Senior Vice President, Late Stage Clinical Development and Medical Affairs GlobeNewswire |
| Aug-15-18 07:35AM | Detailed Research: Economic Perspectives on Neos Therapeutics, Federated National Holding, FutureFuel, Golden Entertainment, Intra-Cellular Therapies, and HTG Molecular Diagnostics What Drives Growth in Today's Competitive Landscape GlobeNewswire |
| Aug-09-18 10:15AM | 7 Biotech Stocks With Big Upcoming Catalysts Kiplinger |
| Aug-06-18 03:19AM | Edited Transcript of ITCI earnings conference call or presentation 2-Aug-18 12:30pm GMT Thomson Reuters StreetEvents |
| Aug-02-18 07:19AM | Intra-Cellular: 2Q Earnings Snapshot Associated Press +5.61% |
| 07:09AM | Intra-Cellular Therapies Provides Corporate Update and Reports Second Quarter 2018 Financial Results GlobeNewswire |
| 06:30AM | Intra-Cellular Therapies, Inc. to Host Earnings Call ACCESSWIRE |
| Jul-26-18 08:00AM | Intra-Cellular Therapies to Host Second Quarter 2018 Financial Results Conference Call and Webcast GlobeNewswire |
| Jul-25-18 09:15AM | Better Buy: Exelixis, Inc. vs. Intra-Cellular Therapies, Inc. Motley Fool |
| Jul-23-18 07:00AM | Intra-Cellular Therapies Announces Publication Highlighting ITI-214 Mechanism of Action and Describing Positive Results in Preclinical Models of Heart Failure GlobeNewswire |
| Jul-21-18 08:44AM | Canaccord Previews Biotech Catalysts In The Second Half: Neurological Drugs In Focus Benzinga |
| Jul-16-18 07:10AM | Complimentary Technical Snapshots on Intercept Pharma and Three More Biotech Stocks ACCESSWIRE |
| Jun-06-18 07:00AM | Intra-Cellular Therapies Initiates Rolling Submission of New Drug Application for Lumateperone for Treatment of Schizophrenia GlobeNewswire +5.36% |
| May-31-18 08:00AM | Intra-Cellular Therapies Presents Data on Symptom Improvement by Lumateperone on Negative Symptoms, Depression, and Social Function in Patients with Schizophrenia at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting GlobeNewswire |
|
|
|
| Intra-Cellular Therapies, Inc., a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative disorders. The company is developing its lead drug candidate, lumateperone for the treatment of schizophrenia, bipolar disorder, behavioral disturbances associated with dementia, autism, and other CNS diseases. It is also developing ITI-002 that inhibits the enzyme phosphodiesterase type 1; ITI-214 for Parkinson's disease; and ITI-333, for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. is headquartered in New York, New York. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Alafi Christopher D | Director | Sep 10 | Buy | 10.26 | 485,000 | 4,974,678 | 4,673,270 | Sep 11 04:30 PM | | Alafi Christopher D | Director | Aug 30 | Buy | 8.52 | 125,000 | 1,065,213 | 4,188,270 | Sep 04 06:24 PM | | Alafi Christopher D | Director | Jun 12 | Buy | 11.73 | 170,000 | 1,993,793 | 170,000 | Jun 14 05:23 PM | | MARCUS JOEL S | Director | May 29 | Option Exercise | 12.45 | 20,000 | 249,000 | 41,671 | May 31 04:35 PM | | Alafi Christopher D | Director | May 14 | Buy | 12.56 | 100,000 | 1,256,350 | 4,053,270 | May 15 06:03 PM | | Hineline Lawrence J. | SVP of Finance CFO | Feb 27 | Option Exercise | 2.74 | 10,400 | 28,496 | 26,232 | Mar 01 07:41 PM | | Hineline Lawrence J. | SVP of Finance CFO | Feb 27 | Sale | 15.00 | 1,000 | 15,000 | 25,232 | Mar 01 07:41 PM | | Mates Sharon | Chairman, President & CEO | Jan 07 | Sale | 12.43 | 6,604 | 82,088 | 1,138,707 | Jan 08 09:28 PM | | Halstead Michael | EVP and General Counsel | Jan 07 | Sale | 12.42 | 3,108 | 38,601 | 191 | Jan 08 09:24 PM | | Hineline Lawrence J. | SVP of Finance CFO | Jan 07 | Sale | 12.42 | 3,108 | 38,601 | 17,032 | Jan 08 09:21 PM | | Vanover Kimberly E. | SVP, Early Stage Clinical Dev. | Jan 07 | Sale | 12.29 | 592 | 7,276 | 27,068 | Jan 08 09:19 PM | | Mates Sharon | Chairman, President & CEO | Jan 04 | Sale | 11.45 | 45,598 | 522,222 | 1,145,311 | Jan 08 09:28 PM | | Halstead Michael | EVP and General Counsel | Jan 04 | Sale | 11.46 | 21,458 | 245,817 | 3,299 | Jan 08 09:24 PM | | Hineline Lawrence J. | SVP of Finance CFO | Jan 04 | Sale | 11.45 | 21,458 | 245,782 | 20,140 | Jan 08 09:21 PM | | Vanover Kimberly E. | SVP, Early Stage Clinical Dev. | Jan 04 | Sale | 11.47 | 9,564 | 109,704 | 27,660 | Jan 08 09:19 PM | | Davis Robert E | SVP, Chief Scientific Officer | Jan 04 | Sale | 11.46 | 9,564 | 109,630 | 43,989 | Jan 08 09:16 PM | | Mates Sharon | Chairman, President & CEO | Jan 02 | Sale | 11.09 | 17,478 | 193,831 | 1,138,707 | Jan 03 09:02 PM | | Halstead Michael | EVP and General Counsel | Jan 02 | Sale | 11.09 | 7,807 | 86,580 | 191 | Jan 03 08:58 PM | | Vanover Kimberly E. | SVP, Early Stage Clinical Dev. | Jan 02 | Sale | 11.10 | 4,834 | 53,657 | 16,861 | Jan 03 08:46 PM | | Davis Robert E | SVP, Chief Scientific Officer | Jan 02 | Sale | 11.11 | 4,834 | 53,706 | 34,744 | Jan 03 08:42 PM | | Hineline Lawrence J. | SVP of Finance CFO | Jan 02 | Sale | 11.09 | 7,807 | 86,580 | 17,032 | Jan 03 08:23 PM | | Mates Sharon | Chairman, President & CEO | Dec 10 | Option Exercise | 1.50 | 50,000 | 75,000 | 1,138,707 | Dec 11 05:55 PM | | Davis Robert E | SVP, Chief Scientific Officer | Dec 06 | Sale | 13.53 | 899 | 12,163 | 30,256 | Dec 07 04:44 PM | | MARCUS JOEL S | Director | Nov 12 | Sale | 17.94 | 7,000 | 125,580 | 78,742 | Nov 13 05:34 PM | | MARCUS JOEL S | Director | Nov 09 | Sale | 18.24 | 25,000 | 456,000 | 85,742 | Nov 13 05:34 PM | | LERNER RICHARD A | Director | Oct 22 | Option Exercise | 1.50 | 12,500 | 18,750 | 66,911 | Oct 24 04:33 PM |
|
